Attralus IPO

attralus.com

Attralus is a biopharmaceutical company focused on creating medicines to improve the lives of patients with systemic amyloidosis. The company uses pan-amyloid removal (PAR) therapeutics to bind and remove toxic amyloid in organs and tissues.

Founded2019
Total Funding to Date$145.45MM
Register for Details

For more details on financing and valuation for Attralus, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Attralus Ticker Symbol

Attralus does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Attralus Stock Price

The stock price for Attralus will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Attralus Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
9/8/2021 Series B $374.61MM $XXX.XX $XXX.XX
9/14/2020 Series A $47.18MM $XXX.XX $XXX.XX
Based on primary financings

Other companies like Attralus in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B